Submission Details
| 510(k) Number | K092275 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | July 28, 2009 |
| Decision Date | March 01, 2011 |
| Days to Decision | 581 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Statement |
K092275 is an FDA 510(k) clearance for the RANDOX ECSTASY (MDMA) ASSAY, a Enzyme Immunoassay, Amphetamine (Class II — Special Controls, product code DKZ), submitted by Randox Laboratories, Ltd. (Crumlin, GB). The FDA issued a Cleared decision on March 1, 2011, 581 days after receiving the submission on July 28, 2009. This device falls under the Chemistry review panel. Regulated under 21 CFR 862.3100.
| 510(k) Number | K092275 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | July 28, 2009 |
| Decision Date | March 01, 2011 |
| Days to Decision | 581 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Statement |
| Product Code | DKZ — Enzyme Immunoassay, Amphetamine |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 862.3100 |